TNFRSF10B and neoplasm: ScDb-dose-dependent tumor growth inhibition was observed with an E:T ratio of 5:1 at both 48 and 96 h of incubation while no effect were seen on TRAIL-R2 negative MDA-MB-468 and BT-474 cells (Figure 3).